Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With $230 million from industry and NIH, the Accelerating Medicines Partnership seeks to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.

You may also be interested in...



NIH Eyes Expansion Of US FDA Partnerships To Gene Therapy

NIH Director Francis Collins describes evolution of existing collaborations and how the two agencies might facilitate development of gene therapy, such as by having a common template for regulatory review.

Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal

President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.

During Shanghai Visit PhRMA Chairman Calls For Regulatory Systems To Support Innovation

During a three-day visit in Shanghai, PhRMA Chairman Robert Hugin met local stakeholders and outlined the organization’s advocacy priorities in China amidst the evolving Drug Administration Law.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS005661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel